Cancer Genetics (NASDAQ:CGIX) Given Media Sentiment Rating of 0.23

Media headlines about Cancer Genetics (NASDAQ:CGIX) have been trending somewhat positive on Thursday, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cancer Genetics earned a coverage optimism score of 0.23 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 44.8807023103223 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Cancer Genetics (NASDAQ:CGIX) traded up $0.08 on Thursday, hitting $2.08. 189,398 shares of the stock traded hands, compared to its average volume of 367,322. The company has a current ratio of 2.01, a quick ratio of 2.01 and a debt-to-equity ratio of 0.18. Cancer Genetics has a fifty-two week low of $1.55 and a fifty-two week high of $5.30. The company has a market cap of $57.49, a price-to-earnings ratio of -2.53 and a beta of 1.10.

A number of analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Cancer Genetics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 29th. HC Wainwright set a $6.00 target price on shares of Cancer Genetics and gave the stock a “buy” rating in a research report on Wednesday, November 29th. ValuEngine lowered shares of Cancer Genetics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, Maxim Group set a $6.00 target price on shares of Cancer Genetics and gave the stock a “buy” rating in a research report on Wednesday, December 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $5.56.

In related news, Director John Pappajohn purchased 150,000 shares of Cancer Genetics stock in a transaction that occurred on Friday, December 8th. The shares were acquired at an average price of $1.86 per share, for a total transaction of $279,000.00. Following the transaction, the director now directly owns 2,781,204 shares in the company, valued at $5,173,039.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 21.30% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This report was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://stocknewstimes.com/2018/01/12/cancer-genetics-cgix-earns-media-sentiment-rating-of-0-23.html.

Cancer Genetics Company Profile

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Insider Buying and Selling by Quarter for Cancer Genetics (NASDAQ:CGIX)

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply